PROTAC as a novel anti-cancer strategy by targeting aging-related signaling
Seminars in Cancer Biology · 2024
DOI: 10.1016/j.semcancer.2024.09.004 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Seminars in Cancer Biology, 2024. Verfasst von Yunhua Peng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China; Center for Mitochondrial Biology and Medicine…. Hauptthemen laut MEDLINE: Aging, Antineoplastic Agents, Neoplasms, Proteolysis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 105 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Key Technologies Research and Development Program.
Abstract (Originalsprache)
Aging and cancer share common cellular hallmarks, including cellular senescence, genomic instability, and abnormal cell death and proliferation, highlighting potential areas for therapeutic interventions. Recent advancements in targeted protein degradation technologies, notably Proteolysis-Targeting Chimeras (PROTACs), offer a promising approach to address these shared pathways. PROTACs leverage the ubiquitin-proteasome system to specifically degrade pathogenic proteins involved in cancer and aging, thus offering potential solutions to key oncogenic drivers and aging-related cellular dysfunction. This abstract summarizes the recent progress of PROTACs in targeting critical proteins implicated in both cancer progression and aging, and explores future perspectives in integrating these technologies for more effective cancer treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China; Center for Mitochondrial Biology and Medicine, The Key Laboratory of Biomedical Information Engineering of Ministry…
- Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China; Key Laboratory for Tumor Precision Medicine of Shaanxi Province, The First Affiliated Hospital of Xi'an Jiaotong Un…
- Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, United States.
- Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, United States. Electronic address: hinuzuka@bidmc.harvard.edu.
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Key Technologies Research and Development Program
Zitieren
APA
Peng, Y., Liu, D., Huang, D., Inuzuka, H., & Liu, J. (2024). PROTAC as a novel anti-cancer strategy by targeting aging-related signaling. Seminars in Cancer Biology. https://doi.org/10.1016/j.semcancer.2024.09.004
Vancouver
Peng Y, Liu D, Huang D, Inuzuka H, Liu J. PROTAC as a novel anti-cancer strategy by targeting aging-related signaling. Seminars in Cancer Biology. 2024. doi:10.1016/j.semcancer.2024.09.004
BibTeX
@article{Peng2024,
author = {Peng, Yunhua and Liu, Donghua and Huang, Daoyuan and Inuzuka, Hiroyuki and Liu, Jing},
title = {PROTAC as a novel anti-cancer strategy by targeting aging-related signaling},
journal = {Seminars in Cancer Biology},
year = {2024},
doi = {10.1016/j.semcancer.2024.09.004}
}
EUVIMED